Litigation Details for Celgene Corporation v. Amneal Pharmaceuticals LLC (D. Del. 2018)

Celgene Corporation v. Amneal Pharmaceuticals LLC (D. Del. 2018)

Docket	1:18-cv-01032	Date Filed	2018-07-12
Court	District Court, D. Delaware	Date Terminated	2018-10-10
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,962,940; 7,427,638; 7,659,302; 7,893,101; 8,455,536; 9,018,243
Link to Docket	External link to docket

Details for Celgene Corporation v. Amneal Pharmaceuticals LLC (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-12				External link to document
2018-07-12	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,962,940 B2 ;7,427,638 B2 ;7,659,302…2018 10 October 2018 1:18-cv-01032 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-07-12	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,962,940 B2; 7,427,638 B2; 7,659,302…2018 10 October 2018 1:18-cv-01032 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Celgene Corporation v. Amneal Pharmaceuticals LLC: Litigation Summary and Patent Analysis

Last updated: August 28, 2026

Celgene Corporation sued Amneal Pharmaceuticals LLC in the U.S. District Court for the District of Delaware over Amneal’s abbreviated new drug application for generic lenalidomide, the active ingredient in Revlimid. The case, Civil Action No. 1:18-cv-01032, was part of the broader Revlimid Hatch-Waxman litigation. The dispute ended without a public trial judgment after the parties resolved the case under confidential settlement terms.

The commercial effect was limited generic entry rather than an immediate unrestricted launch. Celgene’s settlement strategy preserved substantial Revlimid exclusivity while allowing Amneal to enter before the last major patent expiry under agreed conditions.

What drug and regulatory filing were at issue in Celgene v. Amneal?

The case concerned lenalidomide capsules, marketed by Celgene as Revlimid for multiple myeloma, myelodysplastic syndromes associated with a deletion 5q abnormality, and mantle cell lymphoma.

Amneal filed an ANDA seeking approval to market generic lenalidomide capsules. The filing triggered patent litigation under the Hatch-Waxman Act after Amneal served Celgene with Paragraph IV certifications challenging patents listed for Revlimid in the FDA Orange Book.

Item	Case-specific information
Brand drug	Revlimid
Active ingredient	Lenalidomide
Dosage form	Oral capsules
Innovator	Celgene Corporation
Generic applicant	Amneal Pharmaceuticals LLC
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-01032
Judicial officer	Judge Richard G. Andrews
Legal pathway	Hatch-Waxman ANDA litigation
Principal dispute	Validity and infringement of Revlimid patents
Public resolution	Settlement and dismissal rather than a reported merits judgment

Celgene filed the action after receiving Amneal’s Paragraph IV notice. Under 21 U.S.C. § 355(j)(5)(B)(iii), the filing of the patent-infringement action triggered an automatic stay of FDA approval for up to 30 months, subject to statutory exceptions and court action.

What patents protected Revlimid in the Amneal litigation?

The Revlimid patent estate included composition, formulation, polymorph, manufacturing, and method-of-use rights. The Amneal case belonged to a group of related patent actions involving Celgene’s listed lenalidomide patents.

Public litigation records and Revlimid patent listings identify the following patent families as commercially important in the relevant period:

Patent	General subject matter	Approximate ordinary expiration
U.S. Patent No. 6,315,720	Lenalidomide compound and related compositions	October 2022
U.S. Patent No. 7,427,638	Lenalidomide compositions and uses	September 2027
U.S. Patent No. 7,968,569	Therapeutic use, including myelodysplastic syndromes	April 2027
U.S. Patent No. 8,198,262	Lenalidomide treatment methods	June 2027
U.S. Patent No. 8,404,717	Treatment and dosing methods	April 2027
U.S. Patent No. 8,735,428	Methods involving lenalidomide therapy	September 2027
U.S. Patent Nos. 9,101,621 and 9,101,622	Later-generation treatment claims	August 2028

The precise patent claims litigated against Amneal depended on Amneal’s Paragraph IV certifications and the claims Celgene elected to assert. Revlimid litigation frequently involved patents that did not claim only the active molecule. Later patents targeted treatment regimens, patient populations, dosing schedules, and risk-management controls.

The distinction mattered commercially. Even if a generic applicant defeated an older compound patent, Celgene could preserve market protection through later method-of-use patents if the proposed label induced infringement.

What were the main legal issues in the case?

The core issues were standard for a Paragraph IV action:

1. Whether Amneal’s proposed lenalidomide product would infringe asserted patent claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether Celgene could enforce method-of-use claims against Amneal’s proposed labeling.
4. Whether claims directed to restricted distribution and patient-safety procedures were sufficiently tied to the patented therapeutic use.
5. Whether the patents remained enforceable against an ANDA product despite narrowing or carve-out strategies.

Infringement

For composition and formulation claims, infringement would generally turn on the product’s active ingredient, dosage form, excipients, and manufacturing specifications. An ANDA applicant cannot avoid infringement merely by labeling the product differently if the product itself falls within an asserted composition claim.

Method-of-use claims created a more complex issue. Generic applicants may attempt a section viii statement or carve out patented indications from the proposed label. Celgene’s strategy relied on claims covering clinically important uses and dosing regimens that could remain present in the generic label or be encouraged through prescribing and distribution practices.

Validity

Amneal’s Paragraph IV position would have placed the validity of the asserted patents directly in issue. The principal defenses in Revlimid litigation included:

• Obviousness based on thalidomide analogs and prior lenalidomide research.
• Lack of written description or enablement for broad therapeutic claims.
• Anticipation by earlier compound, formulation, or treatment disclosures.
• Double-patenting arguments involving overlapping Celgene patent families.
• Patent-term and priority-date challenges.

The earlier compound patent had a substantially shorter remaining term than several later method patents. That created a potential distinction between chemical entry and commercially useful entry. A generic manufacturer could obtain approval after the compound patent expired while still facing litigation exposure under treatment patents.

When did Celgene and Amneal settle the Revlimid litigation?

The parties resolved the dispute by settlement, and the federal action was dismissed pursuant to the settlement. The agreement was not publicly disclosed in full. Public docket materials do not provide the complete commercial terms, including the precise launch date, royalty structure, authorized-generic provisions, or restrictions on Amneal’s marketing.

The settlement should therefore be analyzed as a negotiated entry arrangement rather than as a finding that Amneal infringed or that Celgene’s patents were valid. No public merits judgment in Celgene v. Amneal established the validity or infringement of the asserted claims.

What did the settlement likely accomplish?

The settlement permitted Celgene to avoid the cost and risk of a trial while retaining control over the timing and conditions of generic entry. For Amneal, the agreement reduced the risk of an injunction, damages exposure, and delayed FDA approval.

In the Revlimid market, settlement value was driven by several factors:

• The high revenue base of Revlimid.
• The difference between compound-patent expiry and later method-patent expiry.
• The limited number of approved manufacturers initially capable of supplying lenalidomide.
• Celgene’s ability to manage access through the RevAssist risk-management system.
• The potential for an authorized generic or licensed generic supply arrangement.
• The risk that a court would uphold later method-of-use patents.

Because the agreement was confidential, the public record does not support attributing a specific launch date or payment structure to Amneal without relying on non-docket sources.

What is the Orange Book status of Revlimid?

Revlimid’s Orange Book status reflected a layered patent estate rather than a single blocking patent. The listed patents covered the active ingredient and later therapeutic applications.

The Orange Book framework is important because an ANDA applicant must address each listed patent through a Paragraph I, II, III, or IV certification, or through a section viii statement for a method-of-use patent that the applicant seeks to omit from its labeling. A Paragraph IV certification exposes the applicant to an infringement action and can trigger the 30-month approval stay.

Regulatory mechanism	Effect in a Revlimid ANDA dispute
Paragraph III certification	Applicant accepts patent delay until expiry
Paragraph IV certification	Applicant challenges validity, enforceability, or infringement
Section viii statement	Applicant seeks to omit a patented indication or use
30-month stay	FDA approval generally paused after timely patent litigation
Settlement	Parties establish a negotiated path to approval and launch

The Orange Book does not itself determine whether a patent is valid or infringed. It identifies patents listed by the NDA holder and creates the regulatory framework for ANDA patent disputes.

When did Revlimid lose exclusivity?

Revlimid lost exclusivity in stages.

The principal compound patent, U.S. Patent No. 6,315,720, had an expiration date in October 2022, subject to any applicable patent-term adjustment or extension. Several later patents extended potential enforcement into 2027 and 2028. Regulatory exclusivity and patent exclusivity were separate issues.

Protection	Commercial significance
New chemical entity exclusivity	Expired years before the Amneal case
Compound patent	Protected the core lenalidomide product until approximately October 2022
Later method patents	Potentially restricted particular indications and regimens through 2027-2028
Orphan-drug exclusivity	Applied to specific indications and periods, not the entire product indefinitely
Settlement rights	Could authorize entry before the final patent expiration

Generic entry after the compound patent expired did not necessarily eliminate all patent risk. The practical launch date depended on the settlement, the scope of the approved label, the remaining Orange Book patents, and the generic manufacturer’s willingness to accept infringement risk.

How strong was Celgene’s patent estate against Amneal?

Celgene’s estate was commercially strong but legally fragmented.

Strengths

Celgene had several advantages:

• A high-value branded product with substantial demand.
• Multiple patent families covering different legal theories.
• Method-of-use claims directed to clinically significant indications.
• A restricted distribution system that complicated generic substitution and supply.
• The ability to assert different patents against different ANDA labels.
• A large financial incentive for Amneal to settle rather than remain in litigation.

Weaknesses

The estate also had structural vulnerabilities:

• The oldest compound patent expired earlier than the later method patents.
• Broad treatment claims faced obviousness and enablement challenges.
• Section viii carve-outs could reduce exposure for some patented uses.
• Patent-by-patent litigation created invalidity risk across multiple proceedings.
• A settlement could force Celgene to accept entry before the latest patent expiry.

The strongest commercial barrier was not necessarily a single patent. It was the combined effect of the core compound patent, later treatment claims, regulatory approval timing, and the distribution controls surrounding Revlimid.

What generic entry risks existed after the Amneal settlement?

The settlement reduced litigation uncertainty but did not eliminate market-entry risks.

Approval risk

FDA approval depended on the ANDA satisfying chemistry, manufacturing, labeling, bioequivalence, and risk-management requirements. Lenalidomide’s restricted distribution system made commercial implementation more complex than for an ordinary oral solid.

Label risk

A generic applicant could face infringement allegations if its label retained indications or dosing instructions covered by Celgene’s method patents. A narrow carve-out could avoid some patent claims but reduce the commercial value of the approved product.

Supply risk

Lenalidomide requires controlled manufacturing and distribution. A manufacturer needs validated production, reliable active-pharmaceutical-ingredient supply, and a compliant system for dispensing to eligible patients and pharmacies.

Substitution risk

State substitution laws and payer contracting determine how quickly a generic captures volume after approval. A generic launch does not automatically produce immediate conversion from the brand.

Price erosion

Multiple approved generic suppliers can cause rapid net-price erosion. A first entrant with settlement rights may capture high initial margins, while later entrants increase discounting and payer pressure.

How did Amneal compare with other Revlimid challengers?

Amneal was one of several generic companies pursuing lenalidomide approval. The competitive landscape included large multinational manufacturers and specialty-generic companies. Teva, Natco, Dr. Reddy’s, Cipla, Sun Pharmaceutical, and other applicants were involved in related Revlimid patent and settlement activity.

Competitive factor	Amneal implication
Number of challengers	Reduced the chance of maintaining a long period of generic scarcity
Settlement timing	Could determine whether Amneal entered before or after competing products
Manufacturing capacity	Affects ability to supply a controlled-distribution product
Patent position	Determines whether entry is licensed, delayed, or at risk
Payer access	Determines conversion from Revlimid to generic lenalidomide
Authorized-generic competition	Could limit Amneal’s launch economics

The value of the Amneal settlement was therefore tied to relative launch position. A license that allowed early entry could be valuable even if several competitors later entered the market.

What revenue exposure did Celgene face?

Revlimid was Celgene’s largest commercial product and a major source of revenue before Bristol Myers Squibb acquired Celgene in 2019. Generic entry created material exposure for the combined company.

The financial impact depended on:

• The timing of the first generic launch.
• The number of licensed and unlicensed entrants.
• The use of authorized-generic supply.
• Reimbursement and substitution rules.
• Volume retention among oncology practices.
• The speed of price erosion.
• The extent to which later method patents delayed unrestricted substitution.

Celgene’s settlement approach traded some future Revlimid revenue for greater certainty over the erosion curve. A controlled launch can produce a slower decline than an immediate multi-player generic event, especially where supply and distribution are specialized.

What is the litigation status of Celgene v. Amneal?

The case concluded through settlement and dismissal. It did not produce a public trial opinion determining that Amneal infringed the asserted patents or that the patents were invalid.

The principal business conclusion is that the case functioned as a negotiated market-entry dispute. The public docket establishes the existence of the Hatch-Waxman action and its resolution, but confidential settlement terms limit analysis of the exact launch rights granted to Amneal.

Key Takeaways

• Celgene v. Amneal involved Amneal’s ANDA for generic lenalidomide capsules.
• The case was filed in the District of Delaware as Civil Action No. 1:18-cv-01032.
• Celgene relied on a layered Revlimid patent estate covering the compound, therapeutic uses, dosing, and related formulations.
• Amneal challenged Celgene’s listed patents through Paragraph IV certifications.
• The action ended in settlement and dismissal, not a public merits judgment.
• The core lenalidomide patent expired in approximately October 2022, while later method patents extended into 2027 and 2028.
• Generic launch economics depended on settlement rights, FDA approval, controlled distribution, label scope, and the number of competing manufacturers.
• The public record does not disclose the full Amneal settlement terms.

FAQs About Celgene v. Amneal and Generic Revlimid Entry

Did Amneal win the Revlimid patent lawsuit?

No public merits ruling established a win for either side. The case was resolved by settlement and dismissed.

Did Celgene’s settlement with Amneal invalidate Revlimid patents?

No. A settlement does not invalidate patents and does not establish infringement. The patents remained legally enforceable unless later invalidated, expired, or disclaimed.

Was Amneal allowed to launch generic lenalidomide before October 2022?

The settlement created a negotiated path to entry, but the complete launch terms were confidential. Public case materials do not establish every commercial restriction or precise launch date.

Did the Revlimid patents cover generic capsules or only the brand product?

The patent estate included claims that could cover lenalidomide compositions, capsules, manufacturing processes, treatment methods, dosing schedules, and patient populations. Coverage depended on the specific claim and the ANDA product.

Why was the Revlimid case commercially important after Celgene became part of Bristol Myers Squibb?

Revlimid was a major revenue product. Generic entry affected Bristol Myers Squibb’s revenue, pricing, market share, and the timing of revenue replacement from newer oncology products.

References

1. Celgene Corporation v. Amneal Pharmaceuticals LLC, No. 1:18-cv-01032-RGA, U.S. District Court for the District of Delaware, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations [Orange Book]. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: Revlimid application and labeling materials. https://www.accessdata.fda.gov

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 6,315,720, 7,427,638, 7,968,569, 8,198,262, 8,404,717, 8,735,428, 9,101,621, and 9,101,622. https://patentcenter.uspto.gov

5. 21 U.S.C. § 355(j). Abbreviated applications for new drugs and patent certifications.

6. 35 U.S.C. § 271(e)(2). Infringement based on submission of an ANDA.